These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 29891106)
1. "No pain, No gain" still true with immunotherapy: When the finger shows the moon, look at the moon! Milano G; Innocenti F; Lacarelle B; Ciccolini J Crit Rev Oncol Hematol; 2018 Jul; 127():1-5. PubMed ID: 29891106 [TBL] [Abstract][Full Text] [Related]
2. Achieving the goals of effective, safe, and individualized cancer care. Roberts SA; Karnes EK; Allen JD; Benner JS; Sigal EV; McClellan M Clin Cancer Res; 2011 Nov; 17(21):6632-3. PubMed ID: 22046023 [No Abstract] [Full Text] [Related]
3. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Mandal R; Chan TA Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038 [TBL] [Abstract][Full Text] [Related]
4. A Review of the Mechanisms and Clinical Implications of Precision Cancer Therapy-Related Toxicity: A Primer for the Radiologist. Thomas R; Howard SA; Laferriere SL; Braschi-Amirfarzan M AJR Am J Roentgenol; 2020 Sep; 215(3):770-780. PubMed ID: 32755160 [No Abstract] [Full Text] [Related]
5. Nucleoside analogs: ready to enter the era of precision medicine? Ciccolini J; Serdjebi C; Le Thi Thu H; Lacarelle B; Milano G; Fanciullino R Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):865-77. PubMed ID: 27218825 [TBL] [Abstract][Full Text] [Related]
6. Emerging role of circulating tumor cells in immunotherapy. Rzhevskiy A; Kapitannikova A; Malinina P; Volovetsky A; Aboulkheyr Es H; Kulasinghe A; Thiery JP; Maslennikova A; Zvyagin AV; Ebrahimi Warkiani M Theranostics; 2021; 11(16):8057-8075. PubMed ID: 34335980 [TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics and breast cancer management: current status and perspectives. Ciccolini J; Fanciullino R; Serdjebi C; Milano G Expert Opin Drug Metab Toxicol; 2015 May; 11(5):719-29. PubMed ID: 25690018 [TBL] [Abstract][Full Text] [Related]
8. Cancer Precision Medicine: Why More Is More and DNA Is Not Enough. Schütte M; Ogilvie LA; Rieke DT; Lange BMH; Yaspo ML; Lehrach H Public Health Genomics; 2017; 20(2):70-80. PubMed ID: 28595192 [TBL] [Abstract][Full Text] [Related]
9. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge. Kostine M; Chiche L; Lazaro E; Halfon P; Charpin C; Arniaud D; Retornaz F; Blanco P; Jourde-Chiche N; Richez C; Stavris C Rev Med Interne; 2017 Aug; 38(8):513-525. PubMed ID: 28214182 [TBL] [Abstract][Full Text] [Related]
10. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956 [TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors renal side effects and management. Rassy EE; Kourie HR; Rizkallah J; Karak FE; Hanna C; Chelala DN; Ghosn M Immunotherapy; 2016 Dec; 8(12):1417-1425. PubMed ID: 28000536 [TBL] [Abstract][Full Text] [Related]
13. Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic. Socinski MA Semin Oncol; 2015 Oct; 42 Suppl 2():S19-28. PubMed ID: 26477471 [TBL] [Abstract][Full Text] [Related]
14. [PHARMACOGENOMICS AND PERSONALIZED MEDICINE: TOWARDS A SYSTEMATIC GENOMIC SCREENING?]. Dideberg V; Segers K; Koopmansch B; Lambert F; Bours V Rev Med Liege; 2015; 70(5-6):251-6. PubMed ID: 26285448 [TBL] [Abstract][Full Text] [Related]
15. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917 [TBL] [Abstract][Full Text] [Related]
16. Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations. Dobbin KK; Cesano A; Alvarez J; Hawtin R; Janetzki S; Kirsch I; Masucci GV; Robbins PB; Selvan SR; Streicher HZ; Zhang J; Butterfield LH; Thurin M J Immunother Cancer; 2016; 4():77. PubMed ID: 27891226 [TBL] [Abstract][Full Text] [Related]
17. Molecular profiling of sarcomas: new vistas for precision medicine. Al-Zaid T; Wang WL; Somaiah N; Lazar AJ Virchows Arch; 2017 Aug; 471(2):243-255. PubMed ID: 28664413 [TBL] [Abstract][Full Text] [Related]
18. Defining drug response for stratified medicine. Lonergan M; Senn SJ; McNamee C; Daly AK; Sutton R; Hattersley A; Pearson E; Pirmohamed M Drug Discov Today; 2017 Jan; 22(1):173-179. PubMed ID: 27818254 [TBL] [Abstract][Full Text] [Related]
19. The Future of Immunotherapy in the Treatment of Cancer. Kottschade LA Semin Oncol Nurs; 2019 Oct; 35(5):150934. PubMed ID: 31477413 [TBL] [Abstract][Full Text] [Related]
20. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. Syn NL; Yong WP; Goh BC; Lee SC Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]